OLDPTSD
Post-Traumatic Stress Disorder (PTSD) is a debilitating mental health condition characterised by severe anxiety, flashbacks, and emotional distress following traumatic events. Recent research into the therapeutic potential of psychedelics, particularly MDMA and psilocybin, indicates promising approaches for treatment-resistant cases of PTSD.
What is OLDPTSD?
PTSD arises from exposure to harrowing events leading to alterations in stress response systems and brain function, particularly impacting areas such as the amygdala and hippocampus.
Symptoms include intrusive memories, avoidance behaviours, negative cognition alterations, and heightened arousal, often resulting in significant impairment in daily functioning.
The pathophysiology involves dysregulation of neurotransmitter systems, such as serotonin, dopamine, and norepinephrine, contributing to anxiety and mood disorders.
Current Treatments
Standard-of-care treatments include psychotherapy approaches such as Cognitive Processing Therapy (CPT) and Prolonged Exposure Therapy (PE), as well as pharmacological interventions like Selective Serotonin Reuptake Inhibitors (SSRIs) including sertraline and paroxetine.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for OLDPTSD.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| MDMA Numerous clinical trials have demonstrated significant symptom reduction in PTSD patients receiving MDMA-assisted therapy. | Large | High | Consistent |
| Psilocybin Research indicates psilocybin's effectiveness in promoting emotional processing and psychological flexibility in PTSD. | Medium | Moderate | Consistent |
| Ketamine Emergency applications showed short-term benefits for PTSD, but variability in long-term outcomes limits consistency. | Medium | Moderate | Inconsistent |
MDMA and OLDPTSD
MDMA, when administered in a controlled therapeutic setting, promotes feelings of safety and emotional openness, allowing patients to confront traumatic memories without overwhelming anxiety. This can facilitate effective therapeutic engagement, resulting in profound reductions in PTSD symptoms.
Psilocybin and OLDPTSD
Psilocybin influences the serotonin system, promoting neuroplasticity and enhancing emotional responses. This effect may help individuals with PTSD process trauma and reframe their negative thought patterns. Clinical trials indicate that a single dose can provide substantial relief from symptoms for months post-treatment.
Key Insights
- 1
MDMA-assisted psychotherapy has shown efficacy in reducing symptoms in treatment-resistant PTSD patients, with several clinical trials reporting significant improvements.
- 2
Psilocybin demonstrates potential for enhancing emotional processing and reducing avoidance, contributing to long-term symptom relief for PTSD.
- 3
Clinical studies indicate that combining psychotherapy with psychedelic compounds may enhance neuroplasticity, providing a unique avenue for healing traumatic memories.
Industrial Landscape
Key industry players include organisations like MAPS (Multidisciplinary Association for Psychedelic Studies) and academic institutions conducting pioneering research on the therapeutic applications of psychedelics in PTSD treatment.
Quick Indicators
\"Ongoing clinical evaluations are investigating OLDPTSD as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with OLDPTSD.